Unlock stock picks and a broker-level newsfeed that powers Wall Street.
editorial-team@simplywallst.com (Simply Wall St)
4 min read
In This Article:
The United Kingdom’s stock market has recently experienced some turbulence, with the FTSE 100 and FTSE 250 indices closing lower amid concerns over China’s sluggish economic recovery and its impact on global trade. This environment highlights the importance of identifying resilient small-cap stocks that can thrive despite broader market challenges, making it crucial to focus on companies with strong fundamentals and growth potential in niche markets.
|
Name |
Debt To Equity |
Revenue Growth |
Earnings Growth |
Health Rating |
|---|---|---|---|---|
|
B.P. Marsh & Partners |
NA |
29.42% |
31.34% |
★★★★★★ |
|
Livermore Investments Group |
NA |
9.92% |
13.65% |
★★★★★★ |
|
London Security |
0.22% |
10.13% |
7.75% |
★★★★★★ |
|
BioPharma Credit |
NA |
7.22% |
7.91% |
★★★★★★ |
|
Andrews Sykes Group |
NA |
2.15% |
4.93% |
★★★★★★ |
|
M&G Credit Income Investment Trust |
NA |
17.28% |
15.80% |
★★★★★★ |
|
VH Global Energy Infrastructure |
NA |
18.30% |
20.03% |
★★★★★★ |
|
Goodwin |
37.02% |
9.75% |
15.68% |
★★★★★☆ |
|
BBGI Global Infrastructure |
0.02% |
3.08% |
6.85% |
★★★★★☆ |
|
AltynGold |
77.07% |
28.64% |
38.10% |
★★★★☆☆ |
We’re going to check out a few of the best picks from our screener tool.
Simply Wall St Value Rating: ★★★★★★
Overview: BioPharma Credit PLC is an investment trust that primarily focuses on investing in interest-bearing debt assets, with a market cap of $1.02 billion.
Operations: The investment trust generates revenue through its focus on interest-bearing debt assets. With a market cap of approximately $1.02 billion, the company leverages its investments to produce returns.
BioPharma Credit, a UK-based financial entity, showcases robust earnings growth of 7.9% annually over five years, although its recent 12.7% yearly increase lagged behind the Capital Markets industry’s 17.4%. The company is debt-free and has demonstrated high-quality earnings while trading at a compelling 29.5% below estimated fair value. Recent activities include repurchasing shares worth $69.65 million, representing 6.51% of outstanding shares, and declaring dividends with an interim payout of 1.75 cents per share for March 2025 alongside a special dividend earlier this year. Earnings for the full year ended December 2024 showed revenue at $150 million with net income climbing to $122 million from the previous year’s $108 million.
-
Get an in-depth perspective on BioPharma Credit’s performance by reading our health report here.
-
Explore historical data to track BioPharma Credit’s performance over time in our Past section.
Simply Wall St Value Rating: ★★★★☆☆
